期刊
FASEB JOURNAL
卷 21, 期 9, 页码 2135-2148出版社
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.06-7685com
关键词
A beta-peptide; cognitive dysfunction
Immunotherapy with A beta is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying A beta cDNA (AAV/A beta). The vaccine reduces the amount of A beta deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/A beta to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased A beta deposition, insoluble A beta, soluble A beta oligomer (A beta*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/A beta-vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/A beta is a safe and effective treatment for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据